At MDRNA we are focused on realizing the potential of RNAi-based therapeutics through the development of a broad-based, state-of-the-art drug discovery platform built upon industry leading expertise in RNA chemistry and oligonucleotide delivery. We bring optimal value to our partners, shareholders and ultimately to patients through the discovery and development of RNAi-based therapeutics against critical unmet medical needs in oncology.

16 March 2010: MDRNA, Inc. to Report Fourth Quarter and Year-End 2009 Results on March 23, 2010 at 4:30 p.m. Eastern Time

15 March 2010: MDRNA, Inc. Demonstrates the Potential for Greater Efficacy in Cancer With an UsiRNA Combination Approach